-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 28, Hengrui Medicine announced that the PARP inhibitor fluzoparib has been approved for a phase Ib/III clinical trial, combined with bevacizumab versus capecitabine and bevacizumab for unresectable or metastatic disease First-line maintenance treatment for colorectal cancer
.
Colorectal cancer is a common malignant tumor.
Its morbidity and mortality rank third and second globally, respectively.
About 40% of patients are in stage IV at the time of diagnosis, and 75%-90% of patients are unresectable
.
At present, the treatment of advanced or metastatic colorectal cancer mainly relies on the combination of chemotherapy and targeted therapy drugs.
Fluzoparib is a class 1.
1 new drug developed by Hengrui Pharmaceuticals, and it is also China's first PARP inhibitor with intellectual property rights
.
The drug was approved for marketing as early as December 2020, and has been approved for two indications for use in platinum-sensitive recurrent ovarian cancer, fallopian tube cancer or cancer of the fallopian tube with germline BRCA mutation (gBRCAm) that has undergone second-line and above chemotherapy.
Fluzoparil combined with chemotherapy or combined targeting has been deployed in multiple tumor types such as breast, ovarian cancer, and digestive tract tumors
.
There are currently many studies in progress .
Note: The original text has been deleted
